




|
|
Catalysts
& Chemicals Division had an excellent year with operating profit
14% up on 1998/99 at £84.8 million.This was led by a strong performance
from both the Autocatalysts and Chemicals businesses. As expected,
profits from the Pharmaceutical Materials business were flat on
the prior year following several years of good growth. Activity
in fuel cells increased dramatically during the year.
Autocatalysts
The Autocatalyst business had an excellent year. The major vehicle
markets of Europe and North America were buoyant with sales in
Europe up around 5%, while in NAFTA vehicle sales were up 9% setting
an all-time record of 19 million units. Sales in Japan were flat
on the prior year and those of the developing economies of ASEAN,
while recovering, were still below the pre-crisis levels of 1996.
Car sales in South America were very poor. Overall, good growth
in vehicle sales, combined with the impact of tighter legislation
around the world, pushed global demand for autocatalysts up by
10%. Johnson Matthey’s unit sales increased by 11%.
 |
| Novel advanced polymer fibre catalyst supports developed by Oy Smoptech Ab |
The
continuing spread of emissions regulations worldwide and the tightening
of standards in Europe and North America are the main drivers
behind a substantial capital investment program.This includes
a new, higher capacity plant in India and a new facility in China
which is being established near Shanghai. While these countries
currently represent only a small fraction of world vehicle demand,
together India and China account for 40% of the world’s population
and both are very serious about tackling environmental pollution.
Continued strong growth in demand for increasingly sophisticated
autocatalysts in the developed economies of Europe and North America
will be met from a new factory currently under construction in
Royston, UK and further expansion of our Devon facility in the
USA. Both factories will use new, state of the art processing
technology which will enable the production of catalysts to higher
specifications.
Chemicals
The platinum group metal (pgm) chemicals and refining businesses
in North America and Europe also had an excellent year with sales
ahead of the good performance achieved in the prior year. There
was continued strong demand for refining services driven by the
increasing prices of the platinum group metals.
 |
| Manufacturing autocatalysts at Johnson Matthey’s production facility in Malaysia |
The
Chemicals business’ new manufacturing facilities for homogeneous
catalysts and particulate, fixed bed catalysts in both the US
and UK are exceeding expectations and are already approaching
full capacity. The high throughput screening methods that Johnson
Matthey has pioneered for catalysis over the last few years are
providing a unique catalyst optimisation service for our customers. A
plant to manufacture specialised heterogeneous catalysts for the
bulk chemicals industry is close to completion and will provide
additional sales, commencing next year. We have agreed a phased
acquisition of Oy Smoptech Ab, a Finnish start-up company that
has developed novel advanced polymer fibre catalyst supports.These
will be combined with our pgm technology to launch a new generation
of anchored homogeneous catalysts.
Demand for pgm chemicals as precursors for autocatalysts and
petroleum refining catalysts is strong and other products are
also contributing to growth in the chemicals business. Alfa Aesar,
the research chemicals business continues to perform well in North
America and is developing its Internet based sales activities.
 |
| Chemists at Johnson Matthey Pharmaceutical Materials develop innovative chemical processes for the manufacture of active pharmaceutical ingredients |
Pharmaceutical Materials
Pharmaceutical
Materials manufactures and markets a range of high value active
pharmaceutical ingredients to both generic and research based
pharmaceutical companies.The business has a significant niche
presence in controlled drugs. 1999/2000 saw excellent growth in
key established products, especially carboplatin, fentanyl and
hydromorphone, while methylphenidate came under pressure due to
increased competition for this generic product. Significant progress
was made on several important new products as well as in two products
in the later stages of clinical trials.
An important programme of investment in the growth of the business
has continued during the year with the commencement of a major
expansion of its facility in West Deptford, New Jersey. Construction
of these expanded facilities, which will include both laboratories
and state of the art manufacturing suites, is scheduled for completion
in 2001.
 |
| Testing the latest generation of fuel processors for residential fuel cells at Johnson Matthey’s new fuel processor laboratory in Devon, USA |
Fuel Cells
1999
was a year of exciting developments in fuel cells.While sales
revenues are small, important collaborative relationships are
being established with leading manufacturers and system developers
in today’s fuel cell industry, which will be crucial to the success
of the business in the future. Johnson Matthey is already well
positioned to be a major supplier of fuel cell catalysts and catalysed
components to amongst others Ballard, XCELLSIS, General Motors
and Plug Power. The company’s fuel cell technology is well regarded
throughout this rapidly growing industry. Over the next 12 months
the business will focus on strengthening its ties with key suppliers
and building robust manufacturing processes in preparation for
expected major growth in demand for its products.A major expansion
of Johnson Matthey’s fuel cell research and development facilities
is underway at Sonning Common, UK and a new fuel processor laboratory
and pilot production unit has been established in Devon, USA.
Research
and Development
Catalysts
& Chemicals Division’s research is focused on providing
customers with world leading technology at competitive prices.
The Autocatalyst business has important R&D programmes to
develop a range of catalyst systems to enhance customer
choice including advanced platinum based alternatives to
palladium only catalysts. Another major focus is the development
of novel emissions systems for both light and heavy duty
diesel engines in response to challenging legislation in
both the US and Europe. Johnson Matthey’s SCRT™ system,
which combines its proven continuously regenerating trap
(CRT™) technology with advanced selective catalytic reduction,
has been hailed as a major breakthrough in this area.The
business continues to make good progress in the development
of high performance catalysts for gasoline direct injection
and other lean burn engines.
R&D in Pharmaceutical Materials focuses on developing manufacturing
processes for new products and ensures that there is a continuous
flow of products in the pipeline. In Chemicals major programmes
include the development of new highly selective catalysts
and ligand systems for pharmaceutical and fine chemicals
applications. A major focus is the development of chiral
catalysts for the manufacture of single isomer drugs.
|
|
|
|